蓝帆医疗: 上海锦天城（青岛）律师事务所关于蓝帆医疗股份有限公司2025年第二次临时股东会的法律意见书

Core Viewpoint - The legal opinion letter from Shanghai Jintiancheng (Qingdao) Law Firm confirms that the second extraordinary general meeting of shareholders of Bluestar Medical Co., Ltd. held on July 7, 2025, complied with relevant laws and regulations, and the voting procedures were valid [2][5][7]. Group 1: Meeting Procedures - The notice for the extraordinary general meeting included details such as the convenor, date, time, and voting methods, ensuring compliance with legal requirements [3][4]. - The meeting was held on July 7, 2025, at 14:00 in the Bluestar Medical office center, with a combination of on-site and online voting [4][5]. Group 2: Attendance and Voting - A total of 11 shareholders attended the meeting in person, representing 259,959,601 shares, which is 25.8119% of the total shares [5][6]. - An additional 574 shareholders participated via online voting, representing 21,077,733 shares [5][6]. - The total number of participants, including both on-site and online, was 578, with a combined share representation of 281,037,334 shares [6]. Group 3: Resolutions and Voting Results - The main resolution discussed was the proposal to lower the conversion price of "Bluestar Convertible Bonds," which was consistent with the agenda provided in the meeting notice [6]. - The voting results showed that 265,958,829 shares approved the resolution, with 58.5152% of small investors voting in favor [6][7].